Ulta Beauty's strong Q1 results signal resilient demand in the U.S. beauty retail market, a key indicator for overseas suppliers and distributors of aesthetic and cosmetic products. The company's broad-based growth across channels and categories suggests sustained consumer spending on beauty, which may influence sourcing and inventory strategies for B2B buyers in the medical aesthetics supply chain.
Earnings beat expectations
Ulta Beauty reported adjusted EPS of $7.74 for the first quarter of fiscal 2026, up 15% year-over-year and well above the consensus estimate of $6.89. Revenue reached $3.16 billion, an 11.1% increase from the prior year, surpassing the $3.12 billion forecast. Same-store sales grew 5.3%, exceeding the expected 4.7%.
After-hours rally reflects investor optimism
Shares closed regular trading at $494.87, down 1.18% on the day, but surged 7.67% in after-hours trading to $532.85. The stock had fallen over 18% year-to-date amid macroeconomic uncertainty, but the earnings surprise triggered strong buying momentum.
CEO cites model strength and execution
Kecia Steelman, Ulta Beauty's President and CEO, stated: "Despite the uncertain macroeconomic environment, we achieved broad-based growth across all channels and key categories, thanks to the strength of our model, focused execution by our team, and the effectiveness of our strategy."
Guidance raised for the year
Based on the strong quarterly performance, Ulta Beauty raised its full-year profit growth guidance, signaling confidence in continued demand.
What buyers should watch
For overseas importers, distributors, and clinic buyers in the medical aesthetics supply chain, Ulta's results indicate that U.S. beauty consumers remain active despite economic headwinds. This may translate into steady demand for aesthetic devices, injectables, and skincare products. Suppliers should monitor Ulta's inventory trends and category performance to align their product offerings with market demand.
Source: Read the original report | Published: June 03, 2026